Napredna pretraga

Pregled bibliografske jedinice broj: 290443

CSF levels of total tau protein, phosphorylated tau epitopes 181, 199 and 231 as markers for early-onset Alzheimer's dementia


Boban, Marina; Grbić, Kristina; Hof, Patrick; Hamann, Christine; Ackl, Nibal; Bader, Benedikt; Danek, Adrian; Šimić, Goran
CSF levels of total tau protein, phosphorylated tau epitopes 181, 199 and 231 as markers for early-onset Alzheimer's dementia // Abstracts of the 10th Congress of the European Federation of Neurological Societies
Glasgow, Velika Britanija, 2006. (poster, međunarodna recenzija, sažetak, znanstveni)


Naslov
CSF levels of total tau protein, phosphorylated tau epitopes 181, 199 and 231 as markers for early-onset Alzheimer's dementia

Autori
Boban, Marina ; Grbić, Kristina ; Hof, Patrick ; Hamann, Christine ; Ackl, Nibal ; Bader, Benedikt ; Danek, Adrian ; Šimić, Goran

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstracts of the 10th Congress of the European Federation of Neurological Societies / - , 2006

Skup
10th Congress of European Federation of Neurological Societies

Mjesto i datum
Glasgow, Velika Britanija, 02-05.09.2006

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Alzheimer's disease; tau protein; cerebrospinal fluid; early-diagnosis; biological markers

Sažetak
Abnormal hyperphosphorylation of the microtubule-associated protein tau and its incorporation into neurofibrillary tangles are major hallmarks of the pathogenesis of Alzheimer's disease (AD). The cerebrospinal fluid (CSF) levels of phosphorylated tau proteins reflect the phosphorylation state of tau in the brain. Using monoclonal antibodies, different tau phosphoepitopes can be sensitively detected in CSF. To determine the diagnostic value of CSF total tau protein (t-tau), tau protein phosphorylated at threonine 181, 199 and 231 (p-tau-181, p-tau-199, p-tau-231) in early onset Alzheimer disease (AD) versus other primary causes of dementia (such as frontotemporal dementia (FTD)). Patients with clinical diagnosis of MCI (mild cognitive impairment), probable and possible AD, as well as FTD and nondemented controls were included in the study. CSF levels of t-tau, p-tau-181, p-tau-199, p-tau-231 were measured using commercially available ELISA kits (Invitrogen-Biosource, Camarillo, CA, USA). Mean CSF t-tau and CSF p-tau-181 levels were significantly elevated in AD patients compared to FTD patients and control subjects. Additionally, in differentiation between AD and FTD, CSF p-tau 181 showed best sensitivity and specificity. Our preliminary results in a rather small group of patients with AD and FTD confirmed earlier findings that p-tau-181 may be an useful, promising biological marker for distinguishing primary causes of dementia (e.g. AD from FTD).

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti, Psihologija

Napomena
European Journal of Neurology (1351-5101) 13 (2006) (S2) 196-197



POVEZANOST RADA


Projekt / tema
0108258

Ustanove
Medicinski fakultet, Zagreb

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE